#United States #San Diego #Bain Capital #Cerevel Therapeutics #Pfizer Inc.

Class Action Filed Against Cerevel Therapeutics Holdings, Inc.

Robbins LLP has informed stockholders that a class action lawsuit has been launched against Cerevel Therapeutics Holdings, Inc., along with Bain Capital Investors, LLC and Pfizer, Inc. This lawsuit addresses alleged violations connected to the trading of Cerevel's publicly traded common stock. The claimants, as outlined in the complaint, comprise a class of individuals and entities adversely impacted during the specified trading period—October 11, 2023, through August 1, 2024.

Key Allegations Against Cerevel

The filing includes allegations that Cerevel misled investors concerning its financial stability and the repercussions of its secondary stock offering. The lawsuit points out that Cerevel's documentation corresponding with its stock offering omitted critical details about AbbVie’s interest in acquiring the company at a significantly higher price than the $22.81 per share offering price. This purportedly led to an artificial deflation of Cerevel's stock until the merger was publicly disclosed.

Moreover, the lawsuit states that Bain Capital, the controlling shareholder, benefited immensely by acquiring Cerevel shares during this period at the depressively low price while reportedly having undisclosed material information regarding AbbVie’s acquisition intention. This was evident when Cerevel announced on December 6, 2023, that AbbVie intended to acquire the company for $45 per share, leading to Bain's realization of over $120 million in profits on shares obtained at the suppressed offering price.

Who Is Affected?

The class action covers a broad range of share transactions. It includes:

• - Individuals who sold or disposed of Cerevel's stock from October 11, 2023, to August 1, 2024.
• - Investors who held shares of Cerevel on January 8, 2024, which were impacted due to misleading information in the company's Proxy statement issued on January 18, 2024.

According to the allegations, the Proxy misrepresented key information regarding the nature of AbbVie’s interest and the implications surrounding it. Those who sold shares right before or during the acquisition talks may also find grounds for recovery due to supposed violations of the Securities Exchange Act.

Taking Action

If you have been affected, you are encouraged to participate in the class action against Cerevel Therapeutics Holdings. Interested shareholders wishing to take an active role as lead plaintiffs must file their paperwork by June 3, 2025. However, even if you choose to remain an absentee class member, you are still entitled to pursue relief from the outcome of the class action. Notably, this representation operates on a contingency fee basis, implying that legal representation incurs no costs unless recoveries are made.

Robbins LLP has established itself as a committed entity in shareholder rights litigation since 2002, working tirelessly to assist investors in regaining losses while enhancing corporate governance and accountability standards.

For updates on potential settlements or to receive alerts on corporate misconduct, shareholders are encouraged to sign up for updates through Robin LLP’s Stock Watch service.

Final Note

The allegations highlighted in this class action suit emphasize the crucial need for transparency and accuracy in corporate communications, especially regarding significant financial movements. Investors and stakeholders are reminded of the importance of remaining vigilant regarding the companies in which they invest, as misinformation can result in considerable financial losses. Stay informed and consider your rights as a shareholder.

For additional information or any inquiries related to the case, please reach out to attorney Aaron Dumas, Jr. directly or captain the hotline at 800-350-6003.